Lymphatic Filariasis Elimination in Haiti
IntroductionHaiti is one of four countries in the Americas Region with ongoing lymphatic filariasis (LF) transmission. It is located in the Caribbean Ocean and occupies the western one-third of the island of Hispaniola. The Dominican Republic, another LF-endemic country, occupies the eastern two-thirds of the island. Quick Facts1
The current program aims to treat ~ 6 million people with mass drug administration (MDA), using either once-yearly albendazole and diethylcarbamazine (DEC) pills or DEC-fortified salt in the period 2003-2008. Initial efforts will concentrate on those at highest risk, the red and dark blue zones on the map. The cost of this program is approximately $1,000,000 per year, funding that will end in 2004. Treatment of the entire at-risk population will require approximately $3 million per year for tablet-based programs or $1.5 million per year for DEC salt. LF in Haiti
85% of Haiti’s population lives in areas at risk of LF transmission. According to a 2001 antigen survey, 117 of 133 communes are endemic for LF. In 2002, an estimated 2,130,000 people (30% of the total population) were thought to be infected2. Surveys are currently being conducted to find the prevalence of lymphedema and hydrocele nationwide. The parasite responsible for LF in Haiti is Wuchereria bancrofti spread mainly by Culex mosquitoes. Goals
Objectives
Strategies
The LF Elimination ProgramOrganization In 2000, the Ministry of Public Health established a national coordinating center for the LF program, along with 4 technical subcommittees – mass treatment, clinical care, social mobilization, and diethylcarbamazine (DEC) fortified salt. In 2003, the national program created a management team to direct activities throughout the country.
Mass Drug Administration Activities Mass drug administration (MDA) campaigns, using once-yearly albendazole and DEC, have been ongoing in Leogane since 2000. The MOPH has begun campaigns in other areas, prioritizing those with greatest prevalence. By 2002, 10% of the at-risk population was covered by MDA campaigns. The program plans to implement MDAs in 16 areas, covering a million people in 2003. DEC-fortified salt use will be the strategy to interrupt transmission in three implementation units. Honeywell International has donated 300 kg of DEC and WHO has donated 3000 kg of powdered DEC to add to local salt. The program expects to treat 100,000 people with fortified salt in 2004. Social Mobilization Posters, flipcharts, radio spots, songs and lymphedema treatment materials have been developed in Haitian Creole. These materials are used for education and advocacy purposes. In 2003, 25 local leaders were educated about LF and how to interrupt transmission, 229 people were trained on how to transmit LF information to the public, and 1,628 local distributors were trained. When drug coverage decreased in Leogane after the second round of MDA, the social mobilization team conducted focus groups to discover the cause. Using results from these groups, they decided to increase awareness regarding adverse side effects and to increase the number of distribution posts. Because of these efforts, coverage increased for the third round, completed in 2002. Health Worker Training A conference was held in 2002 for private
physicians in Haiti. It focused on the epidemiology of the disease and the
objectives of the national elimination program.
Monitoring and Evaluation Four sentinel sites were established in Leogane in 2000, surveying microfilarial (mf) and circulating antigen levels before treatment and after each round of MDA. MF prevalence in sentinel sites has decreased from 9% positive in 2000 to 2% positive in 2002. In 2002, eleven sites in other areas were established. A study of different strategies to assess coverage found little difference between community-based cluster surveys, surveys based on distribution points and school-based surveys. This result will help the national program use cost-effective and accurate ways to monitor the program activities.
Morbidity/Disability Activities In 2002, over 1200 patients were treated
at the LF clinic in Leogane and over 500 were treated at the clinic in Milot.
In 2003, the Leogane clinic treated 176 new patients and the Milot clinic
treated 72 new patients and enrolled 514 people in support groups. In
addition, in total, the Leogane clinic has performed 171 hydrocele surgeries
The program aims to expand LF clinics so that the six areas with greatest LF burden will each have a functioning LF clinic, complete with urologic surgery facilities, by 2004. Economic Research A cost analysis of the Haiti MDA program is ongoing in conjunction with the Emory LF Support Center. The Haiti MOPH is using information from the cost analysis on the first two years of MDA in Leogane to create a budget for the national program. A cost-effectiveness analysis of prevention and treatment programs will be completed in 2004. Operational Research The CDC, in conjunction with the Haitian MOPH and the University of Notre Dame, has been working in Leogane for twenty years, conducting research on strategies to combat LF. Results from the operational research have been used to refine the national program strategy, to improve implementation of country programs globally and to prove the validity of different strategies and activities in controlling LF. OutcomesMass Drug Administration Outcomes
* Disability Prevention Outcomes
Measures of Success
SupportPartners collaborating with the
Haitian Ministry of Public Health to implement
Further funding is required to scale up the program to the 90% of people in at-risk areas that are not currently covered by MDA campaigns. It would expand the number of patient support groups, provide more training in home-based disability treatment, and increase the in-country capacity for hydrocele surgery. These funds would be used in addition to the contributions the Haitian government has already made in personnel and resources. For more information and to provide support to the Haiti LF program or other LF elimination programs contact:
LFSC Publications | Resources | LF Links | LFSC Staff | Contact Us | What's New
|